Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis.

Date publication

novembre 2021

Journal

ESC heart failure

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DEVILLIERS Hervé

Tous les auteurs :
Fischer K, Lellouche N, Damy T, Martins R, Clementy N, Bisson A, Lesaffre F, Espinosa M, Garcia R, Degand B, Serzian G, Jourda F, Huttin O, Guichard JB, Devilliers H, Eicher JC, Laurent G, Guenancia C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34734471

Résumé

Cardiac resynchronization therapy (CRT) is highly effective in dilated cardiomyopathy (DCM) patients with impaired left ventricular ejection fraction (LVEF) and left bundle block branch. In cardiac amyloidosis (CA) patients, left ventricular dysfunction and conduction defects are common, but the potential of CRT to improve cardiac remodelling and survival in this particular setting remains undefined. We investigated cardiovascular outcomes in CA patients after CRT implantation in terms of CRT echocardiographic response and major cardiovascular events (MACEs).

Mots clés

Cardiac amyloidosis, Cardiac resynchronization therapy, Heart failure, Implantable cardioverter defibrillator, Pacemaker

Référence

ESC Heart Fail. 2021 Nov 3;: